Helio Vision

Helio Vision develops a therapy for rare, fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery.

Launch date

2016

Market cap

Enterprise valuation

CAD34m (Public information from Feb 2019)

Lexington Kentucky (HQ)

Date	Investors	Amount	Round
Aug 2016	N/A	$260k	Seed
Feb 2019	Aldeyra Therapeutics	$25.0m Valuation: $25.0m	Acquisition
Total Funding		CAD355k

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Helio Vision